Pan-Hdac Inhibitors Restore PRDM1response to IL-21 in CREBBP Mutated Follicular Lymphoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1153
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Prognostic Impact of Trisomy 21 in Follicular Lymphoma

British Journal of Haematology
Hematology
2018English

JUNB, DUSP2, SGK1, SOCS1 and CREBBP Are Frequently Mutated in T-Cell/Histiocyte Rich Large B-Cell Lymphoma

Haematologica
Hematology
2018English

Follicular Lymphoma

Nature Reviews Disease Primers
Medicine
2019English

Correction: Predictive Biomarkers for Disease Sensitivity in Lymphoma – The Holy Grail for HDAC Inhibitors?

Oncotarget
Oncology
2019English

Pan-Lymphoma Classification

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Simultaneous Bet/Crebbp/Ep300 Targeting Approach Compared to Single Bet or Crebbp/Ep300 Inhibition in Diffuse Large B-Cell Lymphoma (Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

CLP-1 Associates With MyoD and HDAC to Restore Skeletal Muscle Cell Regeneration

Journal of Cell Science
Cell Biology
2010English

Follicular Lymphoma (FL)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Prognostic Factors in Follicular Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy